Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database
David K Packham, Tahira P Alves, Jamie P Dwyer, Robert Atkins, Dick de Zeeuw, Mark Cooper, Shahnaz Shahinfar, Julia B Lewis, Hiddo J Lambers Heerspink
AMERICAN JOURNAL OF KIDNEY DISEASES | W B SAUNDERS CO-ELSEVIER INC | Published : 2012
BACKGROUND: Previous studies have shown that patients with chronic kidney disease, including those with diabetic nephropathy, are more likely to die of cardiovascular disease than reach end-stage renal disease (ESRD). This analysis was conducted to determine whether ESRD is a more common outcome than cardiovascular death in patients with type 2 diabetic nephropathy, significant proteinuria, and decreased kidney function who were selected for participation in a clinical trial. STUDY DESIGN: Retrospective analysis of the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database derived from 2 prospective randomized controlled clinical trials (IDNT [Irbesartan Diabetic..View full abstract
The RENAAL trial was sponsored by Merck & Company. Drs de Zeeuw and Cooper received financial support from Merck & Co for their participation in the steering committee of the RENAAL trial. Dr Shahinfar was an employee of Merck at the time of the conduct of the RENAAL trial. IDNT was sponsored by Bristol Myer Squibb Institute for Medical Research and Sanofi-Synthelabo. Dr Atkins received research grants from Bristol Myer Squibb.